Please login to the form below

Not currently logged in
Email:
Password:

Bavarian Nordic

This page shows the latest Bavarian Nordic news and features for those working in and with pharma, biotech and healthcare.

GlaxoSmithKline reportedly looking to sell select antibiotic brands

GlaxoSmithKline reportedly looking to sell select antibiotic brands

The Stada deal was just the latest in a string of divestments – in January GSK signed a deal worth up to 955m with Bavarian Nordic to offload its travel vaccines Rabipur

Latest news

More from news
Approximately 4 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2015 Deal Watch December 2015

    200. Bavarian Nordic (DK). Janssen. Collaboration, licence. Vaccine platform technology for development of treatment for cancers induced by HPV.

  • The world is our laboratory The world is our laboratory

    The vaccine regimen, which was discovered in a collaborative research programme with the National Institutes of Health, combines our preventative vaccine with a vaccine from Bavarian Nordic, a biotechnology company based ... Our commitment also included

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    1, 100. Bavarian Nordic / BMS. Option to license and commercialise.

  • Pharma deals in March 2015 Pharma deals in March 2015

    Fortunately, at end 2014 Bavarian Nordic was profitable and had over $175m in cash and an R&D cost of around $85m per year. ... One of Bavarian Nordic's sites is in Martinsried, the biotech cluster near Munich.

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    Identifying new agents in asthma and COPD. 196. Bavarian Nordic/J&J. Licence and supply.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics